Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 45.05M P/E - EPS this Y - Ern Qtrly Grth -
Income -53.12M Forward P/E -0.41 EPS next Y - 50D Avg Chg -16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book 0.50 EPS next 5Y 18.30% 52W High Chg -54.00%
Recommedations 3.00 Quick Ratio 5.85 Shares Outstanding 43.28M 52W Low Chg 130.00%
Insider Own 13.74% ROA -16.50% Shares Float 34.45M Beta 0.85
Inst Own 25.24% ROE -79.38% Shares Shorted/Prior 1.96M/1.93M Price 1.24
Gross Margin - Profit Margin - Avg. Volume 277,406 Target Price -
Oper. Margin - Earnings Date Nov 12 Volume 80,149 Change 2.48%
About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Quince Therapeutics, Inc. News
11/13/24 Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
11/12/24 Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
11/11/24 Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
10/24/24 US Penny Stocks To Watch In October 2024
10/14/24 Quince Therapeutics to Participate at Upcoming Investor Conferences
09/03/24 Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
08/16/24 Quince reports data from Phase III Ataxia-Telangiectasia treatment trial
08/15/24 Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
08/13/24 Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
06/26/24 Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
06/25/24 Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
06/04/24 FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
06/03/24 Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
05/13/24 Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
05/06/24 Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
04/01/24 Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
03/08/24 The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
02/22/24 Quince Therapeutics Launches Scientific Advisory Board
02/15/24 Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
02/07/24 Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
QNCX Chatroom

User Image ADSlay Posted - 27 minutes from now

$QNCX you may call me a pumper or a baggie, fine, but at least listen to what this *criminally-under-followed* biotech account had to say about us 6-months ago when we were at $37mm MC -- today we're at $80mm MC, more than double. Now imagine where will we be 6-months from now. go follow him, link: https://x.com/Carl_T_Therapy/status/1795986567481204973 Look at all the acquisitions in this space he points out, and btw, shadow of previous Cortexyme entity is long behind us. Since this tweet in May, Quince had their data published in The Lancet Neurology Journal in their Sep issue as well, just fyi Screenshot:

User Image ADSlay Posted - 8 minutes from now

$QNCX hit another 80-week high today! And mind you, these highs are 'organic', 'ground-up', after meeting milestones and delivering results Fundamentally and technically the most sound $XBI #biotech #microcap on Nasdaq

User Image RobinHoodEU Posted - 5 hours ago

$QNCX smoked that $2 🔥

User Image iAm_Goatz Posted - 6 hours ago

$QNCX 🤑 just the beginning 🪄

User Image Mikshagav Posted - 6 hours ago

$QNCX 🥳🥳🥳

User Image AdamantiumBull Posted - 7 hours ago

$QNCX I can't believe this is still going strong. $ATOS has a much higher prospect of success and demonstrated progress, but the sp continues to lag. Meanwhile QNCX continues on its inexplicable tear. Yes, they've made some progress, but not really enough to justify these amazing moves. Glad I didn't sell my QNCX earlier this year. Almost happened. My sleeper hit for 2024.😘

User Image Alcryptino Posted - 7 hours ago

$QNCX

User Image Wenwenwenwenwenwen Posted - 8 hours ago

$QNCX storm incoming imo….

User Image Wenwenwenwenwenwen Posted - 1 day ago

$QNCX 2+ today?

User Image Alcryptino Posted - 1 day ago

$QNCX

User Image Mikshagav Posted - 1 day ago

$QNCX ☺️

User Image Westieofwallst Posted - 2 days ago

@cheetohottaki listen to $QNCX fireside chats for better

User Image AdamantiumBull Posted - 2 days ago

$QNCX Volume dried up. I guess whoever wanted some shares over the past week already filled their boots.

User Image BullishBanana Posted - 2 days ago

$QNCX order book is getting awfully thin on the sell side. Not much resistance left up to $3.

User Image sunburned1 Posted - 2 days ago

$QNCX

User Image Wenwenwenwenwenwen Posted - 2 days ago

$QNCX pump incoming imo

User Image price_value Posted - 3 days ago

$QNCX last week definitely somebody was buying actively... Today not... volume collapsed again. Did someone the math on Lamond's filing? Did he buy shares on the open market?

User Image Wenwenwenwenwenwen Posted - 3 days ago

$QNCX

User Image sunburned1 Posted - 3 days ago

$QNCX

User Image kb60521 Posted - 3 days ago

$QNCX no nothing, no news, nothing immediately happening, it hit a 52 week high, waiting for some news and something to happen.......

User Image ADSlay Posted - 4 days ago

$QNCX This Board and Management will have us make so much money folks, our heads will spin! DYODD. Just see their journey -- 2025 will be ✨🌟🍾🍾🎉🔥 LIT‼️

User Image ADSlay Posted - 4 days ago

$QNCX Any chartists here? This is for you folks! Attaching Stan Weinstein's stage analysis chart and Quince weekly chart with 30 WMA. Stage 1 was basing, a prolonged period of consolidation - that is key. We're now in the process of Stage 2 - breakout phase. Keep in mind this breakout is organic, as a result of building from ground up and delivering key milestones. While XBI was making dramatic lows this week, we made 52-week highs! Pay attention!

User Image Wenwenwenwenwenwen Posted - 5 days ago

$QNCX wake me up when this hits to $10 at least please, thank you. 💤

User Image ADSlay Posted - 5 days ago

$QNCX See the magnificence of Quince -- we made 52-week highs this week while $XBI tanked dramatically. pay attention to the last paragraph👇

User Image ADSlay Posted - 5 days ago

$QNCX LOT has happened since Aug when only 7 subjects had been enrolled: *32 of 86 subjects enrolled *NASDAQ compliant *Sites increased to 18 from 15 *12 Sites active *Adar1 INCREASED their position *3 BUY Initiations w/ $12, $11, $6 PT *3 poster presentations at 2 conf *Presentation by President/COO *3 more Insider BUYS bringing the total to 22 Insider BUYS in a year As a result, we made a new 52-week high. Congratulations, Longs 🌟🥂✨🎉🍾 Quince story is shaping up to one for the ages.

User Image BullishBanana Posted - 5 days ago

$QNCX ..then I'm not even taking into consideration that Erydel can be used as a treatment for other diseases as stated in the latest quarterly report.

User Image BullishBanana Posted - 5 days ago

$QNCX I've noticed that Biogen is a presenting sponsor in the Ataxia conference that was held this week. $QNCX is one of the gold sponsors. Given Erydel was approved. I would not be surprised of either Pfizer or Biogen would acquire the company in 2-3 years. Pfizer already owns a large amount of shares (2.8M). Some quick Google search implies an median multiple of 5~5.7 in terms of biotech valuation. Quince estimate about 10000 patients worldwide. Pricing comparable to Biogen's Skyclarys (Friedreich Ataxia) $370k/year. So a possible valuation would be; $300k*10k*5=$15bn I would be more than happy with half of that.

User Image Wenwenwenwenwenwen Posted - 6 days ago

$QNCX

User Image kb60521 Posted - 6 days ago

$QNCX I forgot the fundamentals, price is going up here and volume also going up here, what does it mean???

User Image kb60521 Posted - 6 days ago

$QNCX Can't imagine what happens when a tiny firm decides to invest a tiny amount of 5 million into this.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lamond David Director Director Dec 12 Buy 1.02 67,881 69,239 2,347,545 12/14/23
Lamond David Director Director Dec 05 Buy 1.01 57,369 57,943 2,279,664 12/07/23
Lamond David Director Director Nov 29 Buy 0.94 43,134 40,546 2,222,295 12/01/23
Lamond David Director Director Aug 30 Buy 1.32 82,052 108,309 2,179,161 08/31/23
Lamond David Director Director Aug 15 Buy 1.3 250,000 325,000 2,097,109 08/17/23
Thye Dirk Chief Executive Offi.. Chief Executive Officer Aug 08 Buy 1.24 80,000 99,200 360,911 08/09/23
Hannah Brendan Chief Business Offic.. Chief Business Officer Aug 08 Buy 1.22 71,762 87,550 201,555 08/09/23
McLoughlin Margaret Director Director Aug 08 Buy 1.23 8,000 9,840 8,000 08/09/23
McDowell Caryn Gordon Chief Legal & Adm. O.. Chief Legal & Adm. Officer Jun 06 Sell 2.86 10,800 30,888 122,500 06/08/22
McLoughlin Margaret Director Director Oct 08 Option 17 1,000 17,000 1,000 10/12/21
McLoughlin Margaret Director Director Oct 08 Sell 88.93 1,000 88,930 10/12/21
McLoughlin Margaret Director Director Aug 18 Sell 96.62 6,000 579,720 08/18/21
McLoughlin Margaret Director Director Aug 18 Option 17 6,000 102,000 6,000 08/18/21